(See INDICATIONS AND USAGE for Indicated Pathogens.)
SPECTRACEF® (cefditoren pivoxil) Dosage and Administration* Adults and Adolescents ( ≥ 12 Years)  
No dose adjustment is necessary for patients with mild renal impairment (CLcr: 50-80 mL/min/1.73 m²). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (CLcr: 30-49 mL/min/1.73 m²) and 200 mg QD be administered to patients with severe renal impairment (CLcr:  < 30 mL/min/1.73 m²). The appropriate dose in patients with end-stage renal disease has not been determined.
No dose adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). The pharmacokinetics of cefditoren have not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
